Hugel said it has shipped its first batch of Letybo, its botulinum toxin product, to the U.S.

The shipment comes after Hugel received approval from the U.S. FDA for 50-unit and 100-unit versions of Letybo in February. The company officially launched the product in Las Vegas at the end of June.

With this initial shipment, Hugel aims to begin its full-scale entry into the U.S. market.

To ensure rapid market penetration, Hugel is undertaking a variety of strategic efforts, with the distribution and marketing of Letybo in the U.S. being by BENEV, a U.S. cosmeceuticals and medical device distributor.

Hugel plans to leverage BENEV’s extensive distribution channels to ensure the wide availability of Letybo while also engaging in academic marketing and educational activities targeting medical professionals to highlight its safety and efficacy.

"The U.S. is the largest BTX market in the world and continues to show significant growth potential,” a company official said. “This shipment marks our official entry into the U.S. market, and we aim to achieve a 10 percent market share within three years through close collaboration with BENEV.”